PrinterPrezz enticed the Berkeley Catalyst Fund in a series A round that will help expand its medical device 3D printing business.
PrinterPrezz, a US-based medical device 3D printing technology developer, closed a $16m series A round yesterday with investors including Berkeley Catalyst Fund, a venture unit aligned to University of California (UC) Berkeley.
DOV Singularity Fund, an investment unit of D.One Vision Management, led the round with participation from Solvay Ventures on behalf of chemicals producer Solvay and venture capital firm Boutique Venture Partners.
Founded in 2018, PrinterPrezz has developed an end-to-end ecosystem to design, prototype and 3D print medical devices.
The offering includes six products recently sanctioned in the US that are tailored to elements of medical device printing and design, including orthopaedic structure, semiconductors and nanotechnologies.
The series A capital is intended to drive the growth of PrinterPrezz’s business.
Shri Shetty, chief executive of PrinterPrezz, said: “We believe that the future of medical device development is in the joining of novel materials with proprietary technology.
“PrinterPrezz continues to offer opportunities for innovative medical device companies to leverage our infrastructure and know-how to speed their time-to-market.”
